1. Injection of L-tryptophan (750mg/kg body wt.) led to pronounced hypoglycaemia in fed and 48 h-starved rats. 2. The hypoglycaemic effect is blocked by pretreatment with pchlorophenylalanine, compound [Carbidopa: L-a-(3,4-dihydroxybenzyl)-ahydrazinopropionic acid monohydrate] or methysergide, and potentiated by pargyline. 3. 5-Hydroxy-L-tryptophan is more potent and induces a more rapid hypoglycaemia than does tryptophan. Other tryptophan metabolites were not associated with hypoglycaemia. 4. Adrenalectomy increases, and acute experimental diabetes strongly decreases, the sensitivity of rats to tryptophan induction of hypoglycaemia. Diabetic animals were also insensitive to 5-hydroxytryptophan. 5. Metabolite concentration changes in the livers from tryptophan-treated 48 h-starved and diabetic animals were consistent with a rapid inhibition of gluconeogenesis. This did not correlate with the hypoglycaemic response. 6. Tryptophan treatment was associated with a significant increase in the plasma [i6-hydroxybutyrate]/[acetoacetate] ratio; there were no changes in the plasma concentrations of urea, triacylglycerol, non-esterified fatty acids and glycerol. 7. These observations suggest that the hypoglycaemic action of tryptophan is mediated through formation of intracellular 5-hydroxytryptamine, and is unrelated to the inhibition of gluconeogenesis. It is unlikely that this increased synthesis of 5-hydroxytryptamine involves directly either the adrenal glands or the central nervous system. Gullino et al. (1955) first showed that administration of tryptophan to intact rats resulted in hypoglycaemia. This has been generally confirmed in several other studies (Mirsky et al., 1956; Gagliardino et al., 1971 ; McDaniel et al., 1973) , although there are considerable variations between individual reports, particularly with respect to the time-course and intensity of the hypoglycaemic response, and in the conclusions about the mechanism of this effect.
first showed that administration of tryptophan to intact rats resulted in hypoglycaemia. This has been generally confirmed in several other studies (Mirsky et al., 1956; Gagliardino et al., 1971 ; McDaniel et al., 1973) , although there are considerable variations between individual reports, particularly with respect to the time-course and intensity of the hypoglycaemic response, and in the conclusions about the mechanism of this effect.
It has been accepted that tryptophan itself is unlikely to be the direct cause of hypoglycaemia. Mirsky et al. (1956 Mirsky et al. ( , 1957 claimed that several indolic and other metabolites could also elicit decreases in blood glucose concentrations, and ascribed these actions to alterations in circulating insulin availability. In contrast, the demonstration by Lardy and his group (Ray et al., 1966; Veneziale et al., 1967) that glucose synthesis in the isolated perfused liver is inhibited by tryptophan and metabolites derived through the 'kynurenine' pathway (Scheme 1) stimulated the suggestion that hypoglycaemia in the whole animal may be caused by impaired gluconeogenesis, this impairment in turn arising from increases in hepatic quinolinate concentrations (Ray et al., 1966; McDaniel et al., 1973) . This hypothesis is supported by observations that quinolinate administration in vivo produces changes in hepatic Vol. 168 metabolites similar to those seen after tryptophan treatment (Williamson et al., 1971; Spydervold et al., 1974) , although Mirsky et al. (1957) had previously found that quinolinate did not affect blood glucose concentrations in intact rats.
In a study of the role of intracellular monoamines in the regulation of insulin secretion in the mouse, Lundquist et al. (1971) found that administration of low doses of 5-hydroxytryptophan to fed mice pretreated with a monoamine oxidase inhibitor elicited a profound hypoglycaemia. This effect is abolished by inhibitors of aromatic L-amino acid decarboxylase (Scheme 1) and by antagonists of 5-hydroxytryptamine action (Furman, 1974) . This suggests that intracellular 5-hydroxytryptamine may be the active agent in promoting hypoglycaemia under these conditions. The effect of tryptophan itself, however, was differentiated from that of 5-hydroxytryptophan in that only the latter compound was found to be effective in the alloxan-diabetic animal (Furman, 1974) .
Carbohydrate metabolism and its control processes vary from one mammalian species to another (Hanson, 1974; Elliott & Pogson, 1977) Enzymes: (1) tryptophan 5-mono-oxygenase (EC 1.14.16.4); (2) aromatic L-amino acid decarboxylase (EC 4.1.1.28); (3) monoamine oxidase (EC 1.4.3.4); (4) tryptophan aminotransferase (EC 2.6.1.27); (5) tryptophan dioxygenase (EC 1.13.11.11).
>. Inhibition by the agent named; MAOI, monoamine oxidase inhibitors (including pargyline); CIPhe, p-chlorophenylalanine.
teers exhibited responses to tryptophan basically similar to those in the rat (Ajdukiewicz et al., 1968; Furst et al., 1971) .
In the present paper we report a systematic investigation of the mechanism of tryptophan-induced hypoglycaemia in the rat and present a unifying hypothesis consistent with other studies. Some of these data have been presented in preliminary form elsewhere (Smith & Pogson, 1976 Adrenal glands were removed by means of a midline dorsal incision under diethyl ether anaesthesia. Adrenalectomized animals were given 1 % (w/v) NaCl in place of water and were left for 5-8 days before use.
Diabetes was induced in two ways. In most experiments animals were injected intravenously with a solution of alloxan [60mg (rats) or 80mg (mice)/kg body wt.] in 0.9% (w/v) NaCl. These animals were used after 48 h. In some experiments, rats received a similar dose of streptozotocin in 0.9 % NaCl; these were used after 3 days. In all cases diabetes was confirmed by glycosuria (Clinistix; Ames Co., Stoke Poges, Slough, Bucks., U.K.) and subsequent measurement of plasma glucose. Exp.rimentalprotocol Animals were brought to the laboratory immediately before experiments, and were kept together in 1977 the same place over the time course of each experiment.
L-Tryptophan for injection was prepared as follows. Sufficient solid to yield a final concentration of4Omg/ml was addedto 0.9 %NaCl containing0.1 % (w/v) Tween 80. The suspension was heated until all solid had dissolved (near boiling), and was then allowed to cool at room temperature. The resulting suspension of microcrystalline tryptophan was stored at 4°C. L-Tryptophan was administered by intraperitoneal injection through a 16-gauge needle under light diethyl ether anaesthesia. Controls received a similar volume of 0.9 % NaCI, containing 0.1 % Tween 80, under the same conditions.
Tryptamine and 5-hydroxy-L-tryptophan were injected as solutions in 0.9 % NaCl; 5-hydroxytryptamine (as the creatinine sulphate) was injected as a suspension in 0.9 % NaCl, and quinolinate and indol-3-ylacetate as neutralized aqueous solutions.
Pargyline (75mg/kg body wt.), compound MK-486 (68mg/kg body wt.) and methysergide maleate (0.25mg/kg body wt.) were given by intraperitoneal injection of solutions in 0.9 % NaCl at stated times (see the Results and Discussion section) before injection of tryptophan or NaCl. p-Chlorophenylalanine was dissolved in NaOH and reprecipitated with HCI to give a microcrystalline suspension (31.3mg/ml). This was injected intraperitoneally at a dosage of 313 mg/ kg body wt.
All experiments were performed with appropriate simultaneous control animals.
Materials
L-Tryptophan, 5-hydroxy-L-tryptophan, Phosphoenolpyruvate (monocyclohexylammonium salt) was prepared as described by Clark & Kirby (1966) . Pargyline (N-benzyl-N-methylprop-2-ynylamine) was from Abbott Laboratories, Queenborough, Kent Preparation ofblood samplesfor metabolite assays Rats were killed by decapitation and blood was collected in heparinized plastic beakers. Samples (0.5 ml) of whole blood were immediately deproteinized by thorough mixing with 1.5ml of ice-cold 2% (w/v) HCl04. After centrifugation at 2000g for 5min at 4°C, 1.2 ml portions of the supernatant were neutralized with 0.5 M-triethanolamine hydrochloride pH7.4, containing 2M-KOH. After further centrifugation as before at 4°C, the supernatants were decanted and assayed immediately for pyruvate, lactate, ketone bodies and glycerol.
Further portions of whole blood were centrifuged at 2000g for 5min at 4°C. The resulting plasma fractions were stored at -20°C before assay.
Preparation ofliver extracts
Rats were killed by cervical dislocation, and samples ofliver were freeze-clamped as rapidly as possible (Wollenberger et al., 1960 The following compounds were measured by standard procedures: lactate (Gutmann & Wahlefeld, 1974a) , pyruvate and phosphoenolpyruvate (Czok & Lamprecht, 1974) , hydroxybutyrate , acetoacetate , ATP (Jaworek et al., 1974a) , ADP and AMP (Jaworek et al., 1974b) , malate (Gutmann & Wahlefeld, 1974b) , aspartate , glycerol (Garland & Randle, 1962) , nonesterified fatty acid (Duncombe, 1964) , triacylglycerol (Eggstein & Kreutz, 1966) , urea (Fawcett & Scott, 1960) .
Tryptophan was determined fluorimetrically by using a modification (Bloxam & Warren, 1974 ) of the method ofDenckla & Dewey (1967) . 'Bound' and 'free' tryptophan were separated (Lipsett et al., 1973) by dialysis of plasma samples against KrebsHenseleit bicarbonate (Krebs & Henseleit, 1932) gassed with 02/C02 (19: 1). Insulin was measured by radioimmunoassay by using Norit GSX as adsorbent (Albano et al., 1972) . Antibody-bound 1251-labelled insulin was determined in supernatants after separation with charcoal, by fl-liquid-scintillation counting in PCS solubilizer (3H channel, Packard model 3375). The overall counting efficiency was better than 60%.
Glucose was routinely measured with glucose oxidase and peroxidase (Krebs et al., 1963) . Since many compounds, including 5-hydroxytryptamine, are potent inhibitors of colour development in this assay (Nelson & Huggins, 1974) , plasma glucose concentrations were checked by a second method by using hexokinase and glucose 6-phosphate dehydrogenase . No difference was noted in any case between results derived by these two methods.
Results and Discussion
Effects of L-tryptophan and its metabolites on plasma glucose concentrations in the intact rat
The time course of changes in plasma glucose concentrations alter intraperitoneal injection of L-tryptophan is shown in Fig. 1 tions were seen approx. 6 h after the administration of tryptophan; after this time the concentration returned slowly to control values. There has been disagreement in the literature as to whether tryptophan is hypoglycaemic in vivo or not. Howard & Modlinger (1948) and Mann et al. (1949) were unable to detect any effect, but more recent studies record marked changes in blood glucose concentrations (Gullino et al., 1955; Mirsky et al., 1956 Mirsky et al., , 1957 Gagliardino et al., 1971; Bassler & Brinkrolf, 1971; McDaniel et al., 1973) . Even Pretreatment of animals with p-chlorophenylalanine, a long-term non-competitive specific inhibitor of tryptophan and phenylalanine hydroxylases (Koe & Weissman, 1966; Koe, 1971 ; Scheme 1), abolished the hypoglycaemic response to tryptophan (Table 1 ). The inhibitor alone had no effect on this parameter. Inhibition of the 'adjacent' enzyme, aromatic L-amino acid decarboxylase, by compound MK-486 (Scheme 1) had similar results, consistent with the interpretation that the hypoglycaemic response is dependent, in part at least, on conversion into 5-hydroxytryptamine or its further metabolites. That 5-hydroxytryptamine itself is probably the agent responsible in vivo is indicated by experiments with methysergide, a blocker of5-hydroxytryptaminereceptor sites (Franchamps et al., 1960;  Table 1 ). Attempts to obtain a complete inhibition of the effect with higher doses of the drug were unsuccessful, since methysergide, in common with other 5-hydroxytryptamine antagonists, itself produces a stimulatory effect at inappropriate concentrations (Gyermek, 1966) . Vol. 168 (Jarvik, 1970 ; Scheme 1). By itself, pargyline is somewhat hyperglycaemic, an effect possibly attributable to an inhibition of insulin release (Aleyassine & Lee, 1971) . The effect of tryptophan is, however, potentiated by pargyline, with most treated animals dying within 4h (Table 2) . 2.7 ± 0.6** even in the presence of pargyline (results not shown); higher doses of tryptamine were rapidly fatal. Low doses (5 mg/kg body wt.) of 5-hydroxytryptamine itself, administered to pargyline-pretreated 48 h-starved rats, were strikingly hyperglycaemic; the plasma glucose concentration rose from 7.85 ± 0.35mM at zero time to 12.1 + 0.2mm after 30min, and to 13.7 ± 0.6nmm (means ± S.E.M. for four observations in each case) after lIh. The value remained above 12mm for 4h. This result was not surprising in view of the ability of exogenous 5-hydroxytryptamine to stimulate release of catecholamines (Douglas et al., 1967) and block release of insulin (Porte, 1969; Woods & Porte, 1974) .
We found that 5-hydroxytryptophan was an effective hypoglycaemic agent. The effects were manifest both earlier and at much lower doses (Table 4) , and generally confirm previous observations (Lundquist et al., 1971; Furman, 1974) .
The accompanying behavioural disturbances and severe vasoconstriction are indications ofthe accumulation of 5-hydroxytryptamine (Douglas, 1970) .
A number of tryptophan metabolites were tested for their ability to induce hypoglycaemia (Table 3) . Quinolinate,aninhibitorofgluconeogenesis (Williamson et al., 1971; Alvarez & Ray, 1974) , had no effect, in agreement with the results of other workers (Mirsky et al., 1957; Blackshear et al., 1975) . Nevertheless, inhibition of gluconeogenesis must not of necessity cause hypoglycaemia, if peripheral utilization of glucose is equally and simultaneously decreased. The effects of quinolinate on glucose uptake have not, however, been studied.
Indol-3-ylacetate, previously reported to be hypoglycaemic (Mirsky et al., 1957) , elicited in our hands a marked hyperglycaemia. Tryptamine, at low doses, induced very apparent behavioural changes, but did not influence plasma glucose concentrations, Effects of hormonal insufficiency on tryptophanmediated hypoglycaemia Bilateral adrenalectomy renders both the fed and 48 h-starved rat more sensitive to the actions of tryptophan (Table 5 ). Animals given either 100mg or 200mg ofL-tryptophan/kg body wt. died within 5 h; the minimum effective dose is 20mg/kg body wt. In contrast, intact 48 h-starved or fed rats do not even become hypoglycaemic when given 200mg/kg body wt. The sensitivity of the adrenalectomized animal to tryptophan may be a consequence of the toxicity of the amino acid itself, or may result from derangement of tryptophan metabolism. The activity of tryptophan 2,3-dioxygenase, which catalyses the initial step ofthe 'kynurenine' pathway, is induced by glucocorticoid hormones, and is correspondingly decreased in adrenalectomized animals (Rosen & Milholland, 1963; A. Smith, unpublished work).
Since this pathway constitutes a major route of 1977 (Goldfien et al., 1958) .
Acutely alloxan-diabetic rats were apparently insensitive to tryptophan (Table 6 ). There was no significant decrease in plasma glucose concentration even after 12h in fed diabetic animals. Animals rendered diabetic with streptozotocin exhibited similar insensitivity to tryptophan (results not shown). These findings confirm and extend those of Mirsky et al. (1957) and McDaniel et al. (1973) , although it is clearly difficult to dismiss the possibility that tryptophan may elicit the same absolute changes in both normal and diabetic animals, and that these changes are masked by variations in the prevailing high plasma glucose values in the diabetic. Nevertheless, neither tryptophan plus pargyline nor 5-hydroxytryptophan plus pargyline, the two most effective treatments in Vol. 168 the intact animals, had any noticeable effect on plasma glucose values in alloxan-diabetic rats.
The observation that 5-hydroxytryptophan is unable to elicit hypoglycaemia in these experiments is at variance with two earlier studies (Lundquist et al., 1971; Furman, 1974) . Since these investigators used mice rather than rats, we have repeated this experiment with alloxan-diabetic mice (Table 7) . Although control (non-diabetic) animals were clearly responsive, no effect could be demonstrated in diabetic mice. Although no simple explanation can be offered to reconcile these differences, it should be noted that small doses of 5-hydroxytryptophan (10mg/kg body wt.), sufficient to induce hypoglycaemia in the intact mouse, are ineffective in the diabetic animal (Lundquist et al., 1971 (Krebs & Veech, 1969) . These changes confirm and extend other observations (Ray et al., 1966; McDaniel et al., 1973) . The changes do not, however, correlate with the tryptophaninduced alterations in plasma glucose concentrations (see Fig. 1 ). At h after injection the pattern of metabolites is consistent with an inhibition of gluconeogenesis at the level of phosphoenolpyruvate carboxykinase (EC 4.1.1.32), but this coincides with the period of transient hyperglycaemia. McDaniel et al. (1973) and Alvarez & Ray (1974) failed to find any tryptophan-dependent changes in metabolites in livers from diabetic rats, and correlated the lack of a hypoglycaemic response with this apparent lack of inhibition of gluconeogenesis. We have reinvestigated this claim, and found that the pattern of metabolite changes after tryptophan injection is broadly similar in both diabetic and intact rats ( Table 9 ). The only difference of note is that pyruvate accumulates in the tryptophan-treated diabetic liver; the [lactate]/[pyruvate] ratio is unchanged overall. The pattern is thus again consistent with an inhibition of gluconeogenesis. The role of quinolinate in such inhibition is unclear, since this metabolite does not accumulate in livers of diabetic animals (McDaniel etal., 1973) (Ikeda et al., 1965) .
Measurements of blood metabolites in tryptophantreated animals (Table 10) We saw no evidence ofthis effect, although there was a significant fall in the total ketone-body concentration 6h after tryptophan administration. There were no significant changes in the plasma concentrations of urea, triacylglycerol, non-esterified fatty acid or glycerol in tryptophan-treated animals over a 6h period (results not shown).
Tryptophan itself was, not unexpectedly, present at significantly higher concentrations in the plasma of tryptophan-treated than in that of control animals (Table 11 ). Even 6h after injection the concentration was some 4 times that in controls. Measurement of 'bound' and 'free' tryptophan (Knott & Curzon, 1972; Curzon et al., 1973) showed that, although most (approx. 75%Y.) was bound to protein in control plasma, the excess tryptophan in plasma of experimental animals remained largely in the free state (less than 30% bound).
Plasma insulin concentrations were increased some 2.5-fold 3 h after tryptophan administration (Table  11 ), but were not significantly different from control values at other times. This observation agrees with that of Gagliardino et al. (1971) .
General discussion
The pattern of hypoglycaemic responsiveness with tryptophan itself, its metabolites and various inhibitors is consistent with the hypothesis that 5-hydroxytryptamine is the effective agent. The failure of 5-hydroxytryptamine itself to elicit a similar response is unsurprising, since this metabolite is rapidly compartmented into platelets and other tissues (Hagen & Cohen, 1966) , and, at the concenrtrations used, is associated with a complex interaction of pharmacological events (Douglas, 1970) .
Tryptophan may be hydroxylated by at least two distinct enzyme systems. In brain, a specific tryptophan hydroxylase with low activity is present (Guroff, 1975) , whereas in liver and kidney tryptophan hydroxylation depends on phenylalanine hydroxylase, with an unphysiologically high Km for tryptophan (Renson et al., 1961 (Renson et al., , 1962 . In other tissues that synthesize 5-hydroxytryptamine, the nature of the enzymes involved is less clear. Both tryptophan hydroxylase and phenylalanine hydroxylase catalyse rate-limiting steps in the metabolism of their respective substrates (Guroff, 1975) . The regulation of both enzymes is complex and may involve both direct control by metabolites (Fisher & Kaufman, 1973; Lovenberg & Victor, 1974) and changes in total enzyme protein (Zivkovic et al., 1973; McClure et al., 1975; Diez et al., 1976; Sze et al., 1976) . In addition, it has been shown that phenylalanine hydroxylase may be modified by phosphorylation through a cyclic AMP-dependent mechanism (Abita et al., 1976) . The relative effectiveness of 5-hydroxytryptophan as a hypoglycaemic agent may thus be explained in terms of a 'by-pass' of the rate-limiting step of 5-hydroxytryptamine synthesis, and by its rapid transport into, and decarboxylation within, a number of tissues (Udenfriend & Weissbach, 1958) .
There are several possible mechanisms whereby 5-hydroxytryptamine accumulation might produce hypoglycaemia. The evidence that biogenic amines, including 5-hydroxytryptamine, play a role in the regulation of peptide-hormone secretion (Kamberi et al., 1970 (Kamberi et al., , 1971 Bivens et al., 1973; Marco et al., 1976; Smith & Porte, 1976) suggests that an alteration of endocrine function may be involved. The changes in plasma insulin content in our experiments are, however, insufficient on their own to account for the dramatic hypoglycaemia. Moreover, the function of 5-hydroxytryptamine in the pancreatic fl-cell is inhibition rather than stimulation of insulin release (Lernmark, 1971; Wilson et al., 1974) .
Compound MK-486 is an inhibitor of peripheral aromatic L-amino acid decarboxylase (Porter et al., 1962; Bartholini et al., 1971; Warsh & Stancer, 1976) . The inhibition of tryptophan-dependent hypoglycaemia by this compound suggests that 5-hydroxytryptamine synthesis from injected tryptophan is outside the central nervous system. Further evidence is required before one may speculate fruitfully on the 1977
Time (h) 0 1.5 3 4.5 6 +Tryptophan 2.2 + 0.2*** 1.6 ±0.09*** 1.0 ±0.12** 0.25 ± 0.05*** site of this effect. It is reasonable, however, to discount the theory that the anti-gluconeogenic action of tryptophan explains the hypoglycaemic response. The appearance of hypoglycaemia in the fed animal, and the lack of correlation between liver metabolites and plasma glucose concentrations, indicates that these two events are little, if at all, related. The discrepancy between our results and those of other workers with regard to the changes in liver metabolites in diabetic rats is not easily explained. It may, however, perhaps be attributed to the different animal models used: in our experiments, acute (48 h), but non-ketotic, alloxan-diabetes; in earlier studies, chronic (14 day) alloxan-diabetes. The longer period of less-profound diabetes may permit slow adaptations of enzyme activities with consequent alteration of metabolic flux patterns.
